Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,106
Employees15,106
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,106
Employees15,106

REGN Key Statistics

Market cap
63.60B
Market cap63.60B
Price-Earnings ratio
14.89
Price-Earnings ratio14.89
Dividend yield
0.30%
Dividend yield0.30%
Average volume
982.33K
Average volume982.33K
High today
$605.18
High today$605.18
Low today
$585.10
Low today$585.10
Open price
$586.87
Open price$586.87
Volume
631.11K
Volume631.11K
52 Week high
$1,211.20
52 Week high$1,211.20
52 Week low
$476.49
52 Week low$476.49

REGN News

TipRanks 3h
Regeneron’s Promising Phase 3 Trial for Lymphoma Treatment: A Closer Look

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

TipRanks 3h
Regeneron’s Real-World Study on Aflibercept: Key Insights for Investors

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

TipRanks 3h
Regeneron and Sanofi’s Itepekimab Study: A Potential Game-Changer for COPD Treatment

Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study. Elevate Your In...

Analyst ratings

75%

of 28 ratings
Buy
75%
Hold
21.4%
Sell
3.6%

More REGN News

TipRanks 1d
Regeneron’s PNH Study: Long-Term Safety and Efficacy of Pozelimab + Cemdisiran

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...

TipRanks 1d
Regeneron says FDA delayed review of two Eylea HD submissions

Regeneron (REGN) Pharmaceuticals announced that the Food and Drug Administration has extended the target action dates to Q4 of 2025 for two Eylea HD injection r...

TipRanks 6d
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game Changer

Regeneron Pharmaceuticals ((REGN)), Intellia Therapeutics Inc ((NTLA)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: T...

TipRanks 6d
Regeneron’s Cemiplimab: A New Hope for Early-Stage Skin Cancer?

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.